What is Raymond James’ Estimate for TSE:MDP FY2029 Earnings?

Medexus Pharmaceuticals Inc. (TSE:MDP) – Stock analysts at Raymond James issued their FY2029 EPS estimates for Medexus Pharmaceuticals in a report released on Tuesday, November 19th. Raymond James analyst R. Sarugaser forecasts that the company will post earnings per share of $0.89 for the year. Raymond James has a “Outperform” rating and a $4.00 price objective on the stock. The consensus estimate for Medexus Pharmaceuticals’ current full-year earnings is $0.16 per share.

MDP has been the subject of several other research reports. Stifel Canada raised Medexus Pharmaceuticals from a “moderate buy” rating to a “strong-buy” rating in a report on Monday, August 12th. Leede Financial set a C$8.25 price objective on Medexus Pharmaceuticals and gave the company a “speculative buy” rating in a research note on Monday, September 30th. Finally, Stifel Nicolaus lifted their price target on shares of Medexus Pharmaceuticals from C$3.00 to C$3.50 and gave the company a “buy” rating in a report on Thursday, August 22nd. Three analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of C$5.25.

Medexus Pharmaceuticals Price Performance

TSE:MDP opened at C$2.15 on Thursday. Medexus Pharmaceuticals has a one year low of C$1.44 and a one year high of C$3.16. The business has a fifty day moving average price of C$2.48 and a 200-day moving average price of C$2.19. The firm has a market capitalization of C$52.74 million, a price-to-earnings ratio of 43.00 and a beta of 1.96.

Medexus Pharmaceuticals Company Profile

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.